| Document |
Document Title |
|
WO/2022/234965A1 |
The present invention relates to an isoxazolidin-2-yl-substituted heteroaryl derivative and a pharmaceutical composition for cancer prevention or treatment, comprising the compound as an active ingredient. The compound exhibits high inhi...
|
|
WO/2022/233305A1 |
Disclosed is a methylsulfonylurea compound. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/235220A1 |
Disclosed herein are two compounds that are used together to form a PROTAC molecule in situ. Thus, there is a compound of formula Ia and a compound of formula Ib: where R1, R2, L1, L2, X and Y are described herein.
|
|
WO/2022/232919A1 |
The present application relates to compounds, and uses thereof for example for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a viral infection or disease. In an embodi...
|
|
WO/2022/235859A1 |
Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of ...
|
|
WO/2022/235575A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I) or pharmaceuticall...
|
|
WO/2022/235264A1 |
Applicants have developed novel methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection and identifying kinin receptor agonists and antagonists. Novel compositions include one or more active ag...
|
|
WO/2022/235574A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 -kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I) or pharmaceutically...
|
|
WO/2022/233942A1 |
The present invention relates to compounds of the formula (I) wherein R1, R2, R3, L and Y have the designations described herein, or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof. Further, the invention r...
|
|
WO/2022/234193A1 |
The present invention relates to compounds of formula (I),to salts, solvates and solvates of salts thereof, and to pharmaceutical compositions comprising these compounds as active ingredients. The invention further relates to their use a...
|
|
WO/2022/232333A1 |
Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, L, X and Y are as defined herein. The compounds of Formula (I) act as IL4I1 inhibitors and can be useful in preventi...
|
|
WO/2022/232360A1 |
Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical comp...
|
|
WO/2022/232332A1 |
The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical composition...
|
|
WO/2022/228576A1 |
A protein regulator-targeted compound and an application thereof. The compound is a compound represented by formula Ia, Ib or Ic. The compound has a good inhibition effect and protein degradation effect on a KRAS_G12D mutant.
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/225914A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/222730A1 |
Disclosed in the present invention are a compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole, a preparation method therefor and an application thereof. The compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole provided in the p...
|
|
WO/2022/224924A1 |
The present invention addresses the problem of providing: a nitrogen-containing heteroaryl compound which exhibits excellent bactericidal and anti-bacterial activity and excellent safety and which can be synthesized in an industrially ad...
|
|
WO/2022/223039A1 |
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...
|
|
WO/2022/226203A1 |
Disclosed herein are compounds that inhibit 3C-like protease and inhibit replication of viruses, including SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e....
|
|
WO/2022/218289A1 |
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...
|
|
WO/2022/219123A1 |
The present invention relates to ureal derivatives of formula (I) and pharmaceutical compositions comprising such derivatives for use in the treatment of uveal melanoma.
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/219412A1 |
Disclosed herein, in part, is a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: (I) wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10...
|
|
WO/2022/189856A9 |
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...
|
|
WO/2022/216946A1 |
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
|
|
WO/2022/216627A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/214053A1 |
A compound of formula (I) as a USP1 inhibitor or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, and the use thereof in the prevention or t...
|
|
WO/2022/214606A1 |
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...
|
|
WO/2022/216945A1 |
The present disclosure provides compounds, such as compounds of Formula III, and compositions that are MCL1 inhibitors.
|
|
WO/2022/207404A1 |
The application relates to substituted pyrrole carboxamide derivatives of formula (I) which modulate the activity of cycle 7-related protein kinase (Cdc7). The compounds of this invention are therefore useful in treating diseases related...
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/206797A1 |
Compounds of formula A, a method for using said compounds as an EGFR inhibitor, and a pharmaceutical composition comprising said compounds. The compounds can be used to treat, prevent or ameliorate diseases or conditions such as cancers ...
|
|
WO/2022/207494A1 |
The present invention relates to 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/212194A1 |
Compounds of formula (I), wherein the variable substituents are defined herein.
|
|
WO/2022/208356A1 |
Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitor...
|
|
WO/2022/208454A1 |
The present disclosure relates to novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food for the prevention or treatment of cancer, containing the same as ...
|
|
WO/2022/204902A1 |
A benzothiazinone derivative substituted with trifluoromethyl at 6-position, and a preparation method therefor and the use thereof. A series of compounds are obtained by means of changing the benzene ring of the benzothiazinone backbone,...
|
|
WO/2022/206447A1 |
The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also re...
|
|
WO/2022/212815A1 |
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...
|
|
WO/2022/207462A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/206725A1 |
Compounds of general Formula I, II, III, IV, V and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, ...
|
|
WO/2022/211518A1 |
The present invention pertains to a novel compound and a use thereof in treating psoriasis, asthma, or systemic lupus erythematosus. A pharmaceutical composition containing the novel compound of the present invention can not only control...
|
|
WO/2022/207665A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2022/206010A1 |
Disclosed in the present invention is a simple preparation method for isoxazolines, comprising: using aldehyde, p-toluenesulfonyl hydrazide, olefin, and tert-butyl nitrite as a substrate, using copper chloride as a catalyst, using tetram...
|
|
WO/2022/211060A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound repre...
|
|
WO/2022/208262A1 |
The invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q' and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating corona...
|
|
WO/2022/203246A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/202538A1 |
A compound which is represented by formula (1). The present invention provides a compound which has high refractive index and excellent polymerizability, and which is useful as a starting material for an optical material, and the like. (...
|
